Dr Reddys gets Establishment Inspection Report from USFDA for Bollaram facility
New Delhi: Hyderabad-based drug major, Dr Reddy's Laboratories has received an Establishment Inspection Report (EIR) from the US Health regulator for company's active pharmaceutical ingredients (API) manufacturing plant at Bollaram, Telangana.
The US Food and Drug Administration (USFDA) has classified inspection of Bollaram facility as Voluntary Action Initiated (VAI).
Prior to this, USFDA had issued Form 483 with 5 observations for the Bollaram facility. Form 483 is issued to the firm’s management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Dr Reddys was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.
Also Read: Dr Reddys gets 5 USFDA observations for Bollaram plant
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd